Latest News

• 02 August 2021 – Secondary endpoint analysis from Phase 2b trial
• 09 July 2021 – XF-73 Phase 2b data to be presented at ECCMID
• 06 July 2021 – NTCD-M3 RD Agreement with US Dept Veterans Affairs
• 02 July 2021 – Scientific Advisor, Professor Dale Gerding, to chair C. diff. Foundation Symposium
• 29 June 2021 – Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021
• 10 June 2021 – XF-73 data abstract to be presented at 2021 ECCMID
• 07 June 2021 – Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance
• 03 June 2021 – Result of Annual General Meeting
• 02 June 2021 – Positive update on microbiome therapeutic NTCD-M3
• 25 May 2021 – Further information re AGM
• 19 May 2021 – Notice to Register for 2021 AGM
• 06 May 2021 – Destiny Pharma Conference Attendance for May 2021
• 04 May 2021 – Equity Development Research Note ‘Destiny Pharma: M3, another gem in the portfolio’
• 04 May 2021 – Posting of Annual Report and Notice of AGM
• 15 Apr 2021 – Investor Presentation – 22 April 2021 at 1400 BST
• 14 Apr 2021 – Results webcast details
• 14 Apr 2021 – Audited results for the year ended 31 December 2020 and positive Phase 2b data announced post year-end
• 29 Mar 2021 – Destiny Pharma to Join Equity Development Webinar
• 29 Mar 2021 – Destiny Pharma Phase 2b results – Analyst and Investor webcast and conference call details – Monday 29th March at 1100 BST
• 29 Mar 2021 – Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel
• 16 Mar 2021 – Notice of Full Year Results and Clinical Trial Update
• 15 Mar 2021 – Destiny Pharma Announces Agreement with NIAID
• 10 Mar 2021 – Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
• 03 Feb 2021 – Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel
• 02 Feb 2021 – Destiny Pharma to join panel discussion at the 7th Annual LSX World Congress 2021
• 02 Feb 2021 – Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
• 27 Jan 2021 – Destiny Pharma welcomes Matt Hancock’s statement saying G7 will focus on AMR
• 21 Jan 2021 – Destiny Pharma Investor Presentation
• 06 Jan 2021 – Destiny Pharma appoints Stephanie Bewick as Chief Business Officer
• 05 Jan 2021 – Phase 2b trial of XF-73 completes recruitment